Sections
| Title | Starting Page | Number of Pages |
|---|
| Table of Contents | 3 | 10 |
| List of Tables | 7 | 1 |
| List of Figures | 8 | 5 |
| Licensing Strategies In Large Pharmaceutical Companies Introduction | 13 | 3 |
| Licensing Agreement An Authorization | 13 | 2 |
| GBI Research Report Guidance | 15 | 1 |
| Trends in In-licensing and Out-licensing Agreements | 16 | 2 |
| In-Licensing Compensates For Declining Internal R&D | 16 | 1 |
| Licensing Key To Combat Patent Cliff | 16 | 1 |
| Spiraling Cost of Licensing Deals | 16 | 1 |
| Competition to Restock Pipelines | 16 | 1 |
| Biotechs Push Products through Further Stages of Development | 16 | 2 |
| Product Licensing | 18 | 2 |
| Licensing Offsets Deficiencies in Internal Pipelines and Portfolios | 18 | 1 |
| Oncology Therapy Area Spearheads Licensing Agreements in Big Pharma Companies | 18 | 1 |
| Licensing Deals in Asia-Pacific on the Rise | 19 | 1 |
| Technology Licensing Deals | 20 | 1 |
| Importance of Technology In-Licensing | 20 | 1 |
| Technology Licensing With Universities | 20 | 1 |
| Major Licensing Deals of Big Pharma Companies 2010 | 21 | 3 |
| High Value Deals of Big Pharma Players 2010 | 21 | 1 |
| GlaxoSmithKline Enters Into Licensing Agreement with Isis Pharmaceuticals | 21 | 1 |
| Overview | 21 | 1 |
| Deal Rationale | 22 | 1 |
| Sanofi-Aventis enters Into Licensing Agreement with Avila Therapeutics | 22 | 1 |
| Overview | 22 | 1 |
| Deal Rationale | 22 | 1 |
| Boehringer Ingelheim Enters into Licensing Agreement With f-star Biotechnologische | 22 | 1 |
| Overview | 22 | 1 |
| Deal Rationale | 22 | 1 |
| Merck Amends Its Collaboration Agreement with Ariad Pharmaceuticals | 23 | 1 |
| Overview | 23 | 1 |
| Deal Rationale | 23 | 1 |
| AstraZeneca Enters Into Licensing Agreement with Rigel Pharmaceuticals | 23 | 1 |
| Overview | 23 | 1 |
| Deal Rationale | 23 | 1 |
| Licensing Strategies of Major Pharma Companies | 24 | 125 |
| GlaxoSmithKline | 24 | 1 |
| Overview | 24 | 1 |
| Licensing Agreements GSK | 24 | 1 |
| By Value | 25 | 2 |
| By Type | 27 | 1 |
| By Geography | 28 | 1 |
| By Therapy Area | 29 | 1 |
| By Phase | 30 | 1 |
| J&J | 31 | 1 |
| Overview | 31 | 1 |
| Licensing Agreements J&J | 31 | 1 |
| By Value | 32 | 2 |
| By Type | 34 | 1 |
| By Geography | 35 | 1 |
| By Therapy Area | 36 | 1 |
| By Phase | 37 | 1 |
| Roche | 38 | 1 |
| Overview | 38 | 1 |
| Licensing Agreements Roche | 38 | 1 |
| By Value | 39 | 2 |
| By Type | 41 | 1 |
| By Geography | 42 | 1 |
| By Therapy Area | 43 | 1 |
| By Phase | 44 | 1 |
| Abbott | 45 | 1 |
| Overview | 45 | 1 |
| Licensing Agreements Abbott | 45 | 1 |
| By Value | 46 | 1 |
| By Type | 47 | 1 |
| By Geography | 48 | 1 |
| By Therapy Area | 49 | 1 |
| By Phase | 50 | 1 |
| Eli Lilly | 51 | 1 |
| Overview | 51 | 1 |
| Licensing Agreements Eli Lilly | 51 | 1 |
| By Value | 52 | 2 |
| By Type | 54 | 1 |
| By Geography | 55 | 1 |
| By Therapy Area | 56 | 1 |
| By Phase | 57 | 1 |
| Novartis | 58 | 1 |
| Overview | 58 | 1 |
| Licensing Agreements Novartis | 58 | 1 |
| By Value | 59 | 2 |
| By Type | 61 | 1 |
| By Geography | 62 | 1 |
| By Therapy Area | 63 | 1 |
| By Phase | 64 | 1 |
| Sanofi | 65 | 1 |
| Overview | 65 | 1 |
| Licensing Agreements Sanofi | 65 | 1 |
| By Value | 66 | 2 |
| By Type | 68 | 1 |
| By Geography | 69 | 1 |
| By Therapy Area | 70 | 1 |
| By Phase | 71 | 1 |
| Takeda | 72 | 1 |
| Overview | 72 | 1 |
| Licensing Agreements Takeda | 72 | 2 |
| By Value | 74 | 1 |
| By Type | 75 | 1 |
| By Geography | 75 | 1 |
| By Therapy Area | 76 | 1 |
| By Phase | 77 | 1 |
| Pfizer | 78 | 1 |
| Overview | 78 | 1 |
| Licensing Agreements Pfizer | 78 | 1 |
| By Value | 79 | 2 |
| By Type | 81 | 1 |
| By Geography | 82 | 1 |
| By Therapy Area | 83 | 1 |
| By Phase | 84 | 1 |
| Bristol-Myers Squibb | 85 | 1 |
| Overview | 85 | 1 |
| Licensing Agreements Bristol-Myers Squibb | 85 | 1 |
| By Value | 86 | 2 |
| By Type | 88 | 1 |
| By Geography | 89 | 1 |
| By Therapy Area | 90 | 1 |
| By Phase | 91 | 1 |
| Boehringer-Ingelheim | 92 | 1 |
| Overview | 92 | 1 |
| Licensing Agreements Boehringer Ingelheim | 92 | 1 |
| By Value | 93 | 1 |
| Merck &Co. | 94 | 1 |
| Overview | 94 | 1 |
| Licensing Agreements Merck &Co. | 94 | 1 |
| By Value | 95 | 2 |
| By Type | 97 | 1 |
| By Geography | 98 | 1 |
| By Therapy Area | 99 | 1 |
| By Phase | 100 | 1 |
| Bayer | 101 | 1 |
| Overview | 101 | 1 |
| Licensing Agreements Bayer | 101 | 1 |
| By Value | 102 | 2 |
| By Type | 104 | 1 |
| By Geography | 105 | 1 |
| By Therapy Area | 106 | 1 |
| By Phase | 107 | 1 |
| AstraZeneca | 108 | 1 |
| Overview | 108 | 1 |
| Licensing Agreements AstraZeneca | 108 | 1 |
| By Value | 109 | 2 |
| By Type | 111 | 1 |
| By Geography | 112 | 1 |
| By Therapy Area | 113 | 1 |
| By Phase | 114 | 1 |
| Astellas | 115 | 1 |
| Overview | 115 | 1 |
| Licensing Agreements Astellas | 115 | 1 |
| By Value | 116 | 2 |
| By Type | 118 | 1 |
| By Geography | 119 | 1 |
| By Therapy Area | 120 | 1 |
| By Phase | 121 | 1 |
| Daiichi-Sankyo | 122 | 1 |
| Overview | 122 | 1 |
| Licensing Agreements Daiichi Sankyo | 122 | 1 |
| By Value | 123 | 1 |
| By Type | 124 | 1 |
| By Geography | 125 | 1 |
| By Therapy Area | 126 | 1 |
| By Phase | 127 | 1 |
| Teva Pharma | 128 | 1 |
| Overview | 128 | 1 |
| Licensing Agreements Teva | 128 | 1 |
| By Value | 129 | 3 |
| By Geography | 132 | 1 |
| By Therapy Area | 132 | 1 |
| By Phase | 133 | 1 |
| Eisai | 134 | 1 |
| Overview | 134 | 1 |
| Licensing Agreements Eisai | 134 | 1 |
| By Value | 135 | 1 |
| By Type | 136 | 1 |
| By Geography | 137 | 1 |
| By Therapy Area | 138 | 1 |
| By Phase | 139 | 1 |
| Baxter | 140 | 1 |
| Overview | 140 | 1 |
| Licensing Agreements Baxter | 140 | 1 |
| By Value | 141 | 1 |
| By Type | 142 | 1 |
| By Therapy Area | 143 | 1 |
| Amgen | 144 | 1 |
| Overview | 144 | 1 |
| Licensing Agreements Amgen | 144 | 1 |
| By Value | 145 | 1 |
| By Geography | 146 | 1 |
| By Therapy Area | 147 | 1 |
| By Phase | 148 | 1 |
| Licensing Strategies In Large Pharmaceutical Companies Appendix | 149 | 5 |
| Market Definitions | 149 | 1 |
| Abbreviations | 149 | 1 |
| Research Methodology | 149 | 3 |
| Coverage | 150 | 1 |
| Secondary Research | 150 | 1 |
| Primary Research | 150 | 1 |
| Expert Panel Validation | 151 | 1 |
| Section Wise Methodology | 151 | 2 |
| Trends in In-licensing and Out-licensing Agreements | 151 | 1 |
| Product Licensing | 151 | 1 |
| Technology Licensing Deals | 151 | 1 |
| Major Licensing Deals of Big Pharma Companies 2010 | 152 | 1 |
| Licensing Strategies of Major Pharmaceutical Companies | 152 | 1 |
| Contact Us | 152 | 1 |
| Disclaimer | 152 | 1 |
| Sources | 153 | 1 |